Article

Vascular Progenitors from Cord Blood-Derived iPSC Possess Augmented Capacity for Regenerating Ischemic Retinal Vasculature.

Johns Hopkins School of Medicine, Baltimore, MD.
Circulation (Impact Factor: 14.95). 10/2013; 129(3). DOI: 10.1161/CIRCULATIONAHA.113.003000
Source: PubMed

ABSTRACT The generation of vascular progenitors (VP) from human induced pluripotent stem cells (hiPSC) has great potential for treating vascular disorders such as ischemic retinopathies. However, long-term in vivo engraftment of hiPSC-derived VP into retina has not yet been reported. This goal may be limited by the low differentiation yield, greater senescence, and poor proliferation of hiPSC-derived vascular cells. To evaluate the potential of hiPSC for treating ischemic retinopathies, we generated VP from a repertoire of viral-integrated and non-integrated fibroblast and cord blood (CB)-derived hiPSC lines, and tested their capacity for homing and engrafting into murine retina in an ischemia-reperfusion (I/R) model.
VP from human embryonic stem cells (hESC) and hiPSC were generated with an optimized hemato-vascular differentiation system. FACS-purification of human embryoid body (hEB) cells differentially expressing endothelial/pericytic markers identified a CD31(+)CD146(+) VP population with high vascular potency. Episomal CB-iPSC generated these VP with higher efficiencies than fibroblast-iPSC. Moreover, in contrast to fibroblast-iPSC-VP, CB-iPSC-VP maintained expression signatures more comparable to hESC-VP, expressed higher levels of immature vascular markers, demonstrated less culture senescence and sensitivity to DNA damage, and possessed fewer transmitted reprogramming errors. Luciferase transgene-marked VP from hESC, CB-iPSC, and fibroblast-iPSC were injected systemically or directly into the vitreous of retinal I/R-injured adult NOD-SCID mice. Only hESC- and CB-iPSC-derived VP reliably homed and engrafted into injured retinal capillaries, with incorporation into damaged vessels for up to 45 days.
VP generated from CB-iPSC possessed augmented capacity to home, integrate into, and repair damaged retinal vasculature.

1 Bookmark
 · 
128 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A growing body of work has raised concern that many human pluripotent stem cell (hPSC) lines possess tumorigenic potential following differentiation to clinically relevant lineages. In this review, we highlight recent work characterizing the spectrum of cancer-like epigenetic derangements in human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC) that are associated with reprogramming errors or prolonged culture that may contribute to such tumorigenicity. These aberrations include cancer-like promoter DNA hypermethylation and histone marks associated with pluripotency, as well as aberrant X-chromosome regulation. We also feature recent work that suggests optimized high-fidelity reprogramming derivation methods can minimize cancer-associated epigenetic aberrations in hPSC, and thus ultimately improve the ultimate clinical utility of hiPSC in regenerative medicine.
    Current Opinion in Genetics & Development 10/2014; 28:43–49. DOI:10.1016/j.gde.2014.09.008 · 8.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Induced pluripotent stem cells (iPSC) have become the most promising candidates for in-vitro modeling of motor neuron diseases (MND) such as Amyotrophic Lateral Sclerosis (ALS) and possibly for future therapeutic implementation in regenerative medicine. We here present for the first time the differentiation of human cord blood derived iPSC (hCBiPSC) into motor neurons (MN), the cell type primarily affected in ALS. In contrast to iPSC generated from adult tissue the hCBiPSC used in this study hold the promise of lower genetic mutations burden or epigenetic alterations which makes them ideal candidates for transplantation studies. After 18 days of in-vitro differentiation the MNs stained positive for neuronal and for MN specific markers accompanied by respective gene expression patterns. To demonstrate that hCBiPSC can be differentiated into functional MNs, the cells were characterized by calcium-imaging and patch-clamp analysis. Calcium-imaging detected the expression of functional voltage-dependent calcium and ligand-gated channels of several important neurotransmitters. Using whole-cell patch-clamp recordings, we observed functional neuronal properties like sodium-inward currents and action potentials. Some cells showed spontaneous action potentials and synaptic activity that are signs of essential functional maturation. Having established a rapid and efficient method to generate functional MNs from hCBiPSC, we demonstrate the differentiation potential of genetically unbiased hCBiPSC as promising source for transplantation studies and also create a framework for future in-vitro modelling.
    Stem Cells and Development 07/2014; 23(24). DOI:10.1089/scd.2014.0180 · 4.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vision is the sense that we use to navigate the world around us. Thus it is not surprising that blindness is one of people’s most feared maladies. Heritable diseases of the retina, such as age-related macular degeneration and retinitis pigmentosa, are the leading cause of blindness in the developed world, collectively affecting as many as one-third of all people over the age of 75, to some degree. For decades, scientists have dreamed of preventing vision loss or of restoring the vision of patients affected with retinal degeneration through drug therapy, gene augmentation or a cell-based transplantation approach. In this review we will discuss the use of the induced pluripotent stem cell technology to model and develop various treatment modalities for the treatment of inherited retinal degenerative disease. We will focus on the use of iPSCs for interrogation of disease pathophysiology, analysis of drug and gene therapeutics and as a source of autologous cells for cell transplantation and replacement.
    Progress in Retinal and Eye Research 11/2014; 44. DOI:10.1016/j.preteyeres.2014.10.002 · 9.90 Impact Factor